Crossref
journal-article
Springer Science and Business Media LLC
Nature Medicine (297)
References
61
Referenced
334
-
Couch, F.J. et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N. Engl. J. Med. 336, 1409–1415 (1997).
(
10.1056/NEJM199705153362002
) / N. Engl. J. Med. by FJ Couch (1997) -
Peto, J. et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer [see comments]. J. Natl. Cancer Inst. 91, 943–949 (1999).
(
10.1093/jnci/91.11.943
) / J. Natl. Cancer Inst. by J Peto (1999) - Easton, D.F., Bishop, D.T., Ford, D. & Crockford, G.P. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am. J.Hum. Genet. 52, 678–701 (1993). / Am. J.Hum. Genet. by DF Easton (1993)
-
Struewing, J.P., Tarone, R.E., Brody, L.C., Li, F.P. & Boice, J.D. Jr. BRCA1 mutations in young women with breast cancer. Lancet 347, 1493 (1996).
(
10.1016/S0140-6736(96)91732-8
) / Lancet by JP Struewing (1996) -
Fodor, F.H. et al. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am. J. Hum. Genet. 63, 45–51 (1998).
(
10.1086/301903
) / Am. J. Hum. Genet. by FH Fodor (1998) -
Easton, D.F., Narod, S.A., Ford, D. & Steel, M. The genetic epidemiology of BRCA1. Breast Cancer Linkage Consortium. Lancet 344, 761 (1994).
(
10.1016/S0140-6736(94)92256-X
) / Lancet by DF Easton (1994) -
Easton, D.F., Ford, D. & Bishop, D.T. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 56, 265–271 (1995).
(
10.1002/ajmg.1320560305
) / Am. J. Hum. Genet. by DF Easton (1995) -
Struewing, J.P. et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med. 336, 1401–1408 (1997).
(
10.1056/NEJM199705153362001
) / N. Engl. J. Med. by JP Struewing (1997) -
Ford, D., Easton, D.F., Bishop, D.T., Narod, S.A. & Goldgar, D.E. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343, 692–695 (1994).
(
10.1016/S0140-6736(94)91578-4
) / Lancet by D Ford (1994) - Shih, H. et al. BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers. Clin Cancer Res 6, 4259–4264 (2000). / Clin Cancer Res by H Shih (2000)
-
Miki, Y. et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66–71 (1994).
(
10.1126/science.7545954
) / Science by Y Miki (1994) -
Chapman, M.S. & Verma, I.M. Transcriptional activation by BRCA1. Nature 382, 678–679 (1996).
(
10.1038/382678a0
) / Nature by MS Chapman (1996) -
Zhang, H. et al. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 16, 1713–1721 (1998).
(
10.1038/sj.onc.1201932
) / Oncogene by H Zhang (1998) -
Scully, R. et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88, 265–275 (1997).
(
10.1016/S0092-8674(00)81847-4
) / Cell by R Scully (1997) -
Scully, R. & Livingston, D.M. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 408, 429–432 (2000).
(
10.1038/35044000
) / Nature by R Scully (2000) -
Cortez, D., Wang, Y., Qin, J. & Elledge, S.J. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 286, 1162–1166 (1999).
(
10.1126/science.286.5442.1162
) / Science by D Cortez (1999) -
Lee, J.S., Collins, K.M., Brown, A.L., Lee, C.H. & Chung, J.H. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 404, 201–204 (2000).
(
10.1038/35004614
) / Nature by JS Lee (2000) - Larson, J.S., Tonkinson, J.L. & Lai, M.T. A BRCA1 mutant alters G2-M cell cycle control in human mammary epithelial cells. Cancer Res. 57, 3351–3355 (1997). / Cancer Res. by JS Larson (1997)
-
Gowen, L.C., Avrutskaya, A.V., Latour, A.M., Koller, B.H. & Leadon, S.A. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 281, 1009–1012 (1998).
(
10.1126/science.281.5379.1009
) / Science by LC Gowen (1998) -
Zhong, Q. et al. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science 285, 747–750 (1999).
(
10.1126/science.285.5428.747
) / Science by Q Zhong (1999) -
Easton, D.F. & Consortium, T.B.C.L. Cancer risks in BRCA2 mutation carriers. J. Natl. Cancer Inst. 91, 1310–1316 (1999).
(
10.1093/jnci/91.15.1310
) / J. Natl. Cancer Inst. by DF Easton (1999) -
Warner, E. et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 91, 1241–1247 (1999).
(
10.1093/jnci/91.14.1241
) / J Natl Cancer Inst by E Warner (1999) -
Wooster R et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789–92 (1995).
(
10.1038/378789a0
) / Nature by R Wooster (1995) -
Tavtigian, S.V. et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nature Genet. 12, 333–337 (1996).
(
10.1038/ng0396-333
) / Nature Genet. by SV Tavtigian (1996) - Chen, J.J., Silver, D., Cantor, S., Livingston, D.M. & Scully, R. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res. 59, 1752s–1756s (1999). / Cancer Res. by JJ Chen (1999)
-
Connor, F. et al. Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nature Genet. 17, 423–430 (1997).
(
10.1038/ng1297-423
) / Nature Genet. by F Connor (1997) - Friedman, L.S. et al. Thymic lymphomas in mice with a truncating mutation in Brca2. Cancer Res. 58, 1338–1343 (1998). / Cancer Res. by LS Friedman (1998)
-
Patel, K.J. et al. Involvement of Brca2 in DNA repair. Mol. Cell 1, 347–357 (1998).
(
10.1016/S1097-2765(00)80035-0
) / Mol. Cell by KJ Patel (1998) -
Sharan, S.K. et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386, 804–810 (1997).
(
10.1038/386804a0
) / Nature by SK Sharan (1997) -
Nasmyth K. Peters JM . Uhlmann F. Splitting the chromosome: cutting the ties that bind sister chromatids. Science. 288,1379–1385 (2000).
(
10.1126/science.288.5470.1379
) / Science. by K Nasmyth (2000) -
Boardman, L.A. et al. Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann. Int. Med. 128, 896–899 (1998).
(
10.7326/0003-4819-128-11-199806010-00004
) / Ann. Int. Med. by LA Boardman (1998) -
Liaw, D. et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature Genet. 16, 64–67 (1997).
(
10.1038/ng0597-64
) / Nature Genet. by D Liaw (1997) -
Wooster, R. et al. A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nature Genet. 2, 132–134 (1992).
(
10.1038/ng1092-132
) / Nature Genet. by R Wooster (1992) -
Lobaccaro, J.M. et al. Androgen receptor gene mutation in male breast cancer. Hum. Mol. Genet. 2, 1799–1802 (1993).
(
10.1093/hmg/2.11.1799
) / Hum. Mol. Genet. by JM Lobaccaro (1993) -
Malkin, D. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233–1238 (1990).
(
10.1126/science.1978757
) / Science by D Malkin (1990) - Morrell, D., Cromartie, E. & Swift, M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J. Natl. Cancer Inst. 77, 89–92 (1986). / J. Natl. Cancer Inst. by D Morrell (1986)
-
Swift, M., Reitnauer, P.J., Morrell, D. & Chase, C.L. Breast and other cancers in families with ataxia-telangiectasia. N. Engl. J. Med. 316, 1289–1294 (1987).
(
10.1056/NEJM198705213162101
) / N. Engl. J. Med. by M Swift (1987) -
Swift, M., Morrell, D., Massey, R.B. & Chase, C.L. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N. Engl. J. Med. 325, 1831–1836 (1991).
(
10.1056/NEJM199112263252602
) / N. Engl. J. Med. by M Swift (1991) -
Inskip, H.M., Kinlen, L.J., Taylor, A.M., Woods, C.G. & Arlett, C.F. Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia. Br. J. Cancer 79, 1304–1307 (1999).
(
10.1038/sj.bjc.6690209
) / Br. J. Cancer by HM Inskip (1999) -
Janin, N. et al. Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families. Br. J. Cancer 80, 1042–1045 (1999).
(
10.1038/sj.bjc.6690460
) / Br. J. Cancer by N Janin (1999) -
Broeks, A. et al. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am. J. Hum. Genet. 66, 494–500 (2000).
(
10.1086/302746
) / Am. J. Hum. Genet. by A Broeks (2000) -
FitzGerald, M.G. et al. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nature Genet. 15, 307–310 (1997).
(
10.1038/ng0397-307
) / Nature Genet. by MG FitzGerald (1997) -
Izatt, L. et al. Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer. Genes Chrom. Cancer 26, 286–294 (1999).
(
10.1002/(SICI)1098-2264(199912)26:4<286::AID-GCC2>3.0.CO;2-X
) / Genes Chrom. Cancer by L Izatt (1999) - Chen, J., Birkholtz, G.G., Lindblom, P., Rubio, C. & Lindblom, A. The role of ataxia-telangiectasia heterozygotes in familial breast cancer. Cancer Res. 58, 1376–1379 (1998). / Cancer Res. by J Chen (1998)
- Vorechovsky, I. et al. ATM mutations in cancer families. Cancer Res. 56, 4130–4133 (1996). / Cancer Res. by I Vorechovsky (1996)
-
Laake, K. et al. Screening breast cancer patients for Norwegian ATM mutations. Br. J. Cancer 83, 1650–1653 (2000).
(
10.1054/bjoc.2000.1519
) / Br. J. Cancer by K Laake (2000) -
Kainu, T. et al. Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc. Natl. Acad. Sci. USA 97, 9603–9608 (2000).
(
10.1073/pnas.97.17.9603
) / Proc. Natl. Acad. Sci. USA by T Kainu (2000) - Thompson, D. et al. Chromsome 13q: Two genes too many? Proc. Am. Assoc. Cancer Res. (2001).
-
Ford, D. et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J.Hum. Genet. 62, 676–689 (1998).
(
10.1086/301749
) / Am. J.Hum. Genet. by D Ford (1998) - Lakhani, S.R. et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin. Cancer Res. 6, 782–789 (2000). / Clin. Cancer Res. by SR Lakhani (2000)
-
Hedenfalk, I. et al. Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med. 344, 539 (2001).
(
10.1056/NEJM200102223440801
) / N. Engl. J. Med. by I Hedenfalk (2001) -
Anonymous. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br. J. Cancer 83, 1301–1308 (2000).
(
10.1054/bjoc.2000.1407
) -
Claus, E.B., Schildkraut, J., Iversen, E.S., Berry, D. & Parmigiani, G. Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. J. Natl. Cancer. Inst. 90, 1824–1890 (1998).
(
10.1093/jnci/90.23.1824
) / J. Natl. Cancer. Inst. by EB Claus (1998) -
Krontiris, T.G., Devlin, B., Karp, D.D., Robert, N. J. & Risch, N. An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. N. Engl. J. Med. 329, 517–523 (1993).
(
10.1056/NEJM199308193290801
) / N. Engl. J. Med. by TG Krontiris (1993) -
Phelan, C.M. et al. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nature Genet. 12, 309–311 (1996).
(
10.1038/ng0396-309
) / Nature Genet. by CM Phelan (1996) -
Rebbeck, T. et al. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen receptor CAG repeat. Am. J. Hum. Genet. 64, 1371–1377 (1999).
(
10.1086/302366
) / Am. J. Hum. Genet. by T Rebbeck (1999) - Park, J.J. et al. Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Res. 60, 5946–5949 (2000). / Cancer Res. by JJ Park (2000)
- Tirkkonen, M. et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res. 57, 1222–1227 (1997). / Cancer Res. by M Tirkkonen (1997)
-
Kruglyak, L. Prospects for whole-genome linkage disequilibrium mapping of common disease genes. Nature Genet. 22, 139–144 (1999).
(
10.1038/9642
) / Nature Genet. by L Kruglyak (1999) -
Eisen, A., Rebbeck, T.R., Wood, W.C. & Weber, B.L. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J. Clin. Oncol. 18, 1980–1995 (2000).
(
10.1200/JCO.2000.18.9.1980
) / J. Clin. Oncol. by A Eisen (2000) -
Peto, J. & Mack, T.M. High constant incidence in twins and other relatives of women with breast cancer. Nature Genet. 26, 411–414 (2000).
(
10.1038/82533
) / Nature Genet. by J Peto (2000)
Dates
Type | When |
---|---|
Created | 23 years ago (July 26, 2002, 4:43 a.m.) |
Deposited | 2 years, 3 months ago (May 18, 2023, 6:25 p.m.) |
Indexed | 1 day, 8 hours ago (Aug. 24, 2025, 7:06 p.m.) |
Issued | 24 years, 3 months ago (May 1, 2001) |
Published | 24 years, 3 months ago (May 1, 2001) |
Published Print | 24 years, 3 months ago (May 1, 2001) |
@article{Nathanson_2001, title={Breast cancer genetics: What we know and what we need}, volume={7}, ISSN={1546-170X}, url={http://dx.doi.org/10.1038/87876}, DOI={10.1038/87876}, number={5}, journal={Nature Medicine}, publisher={Springer Science and Business Media LLC}, author={Nathanson, Katherine N. and Wooster, Richard and Weber, Barbara L.}, year={2001}, month=may, pages={552–556} }